KIF18A-IN-7|cas:2914878-00-3|西域试剂

KIF18A-IN-7,98.09%

产品编号：Bellancom-153066| CAS NO：2914878-00-3| 分子式：C₂₇H₃₅N₃O₅S₂| 分子量：545.71

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-153066	￥3800.00	杭州北京（现货）
Bellancom-153066	￥6200.00	杭州北京（现货）
Bellancom-153066	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

KIF18A-IN-7

产品介绍

KIF18A-IN-7 (Compound 22) 是一种具有口服活性的 KIF18A 抑制剂，抑制 KIF18A 微管依赖性 ATPase 活性，IC₅₀ 为 9.4 nM。

生物活性

KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC₅₀ of 9.4 nM against KIF18A microtubule-dependent ATPase activity.

体外研究

KIF18A-IN-7 (Compound 22; 7 days) 抑制 JIMT-1、NIH-OVCAR3 和 HCC-15 细胞活力，IC₅₀ 分别为 0.0078、0.0097 和 0.011 μM。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HCC-15, JIMT-1 and NIH-OVCAR3
Concentration:
Incubation Time:	7 days
Result:	Inhibited cell viability with IC₅₀s of 0.0078, 0.0097 and 0.011 μM against JIMT-1, NIH-OVCAR3 and HCC-15 cells, respectively.

体内研究
(In Vivo)

KIF18A-IN-7 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID Beige mice, HCC15 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice a day for 1 month
Result:	Inhibited tumor growth by 30±15%, 72±6% and 82±9% at 10, 30 and 60 mg/kg, respectively.

Animal Model:	Balb/C nude mice, OVCAR3 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, once a day for 1 month
Result:	Inhibited tumor growth by 24±26%, 72±17% and 82±10% at 10, 30 and 60 mg/kg, respectively.

体内研究

KIF18A-IN-7 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID Beige mice, HCC15 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice a day for 1 month
Result:	Inhibited tumor growth by 30±15%, 72±6% and 82±9% at 10, 30 and 60 mg/kg, respectively.

Animal Model:	Balb/C nude mice, OVCAR3 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, once a day for 1 month
Result:	Inhibited tumor growth by 24±26%, 72±17% and 82±10% at 10, 30 and 60 mg/kg, respectively.

体内研究

KIF18A-IN-7 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID Beige mice, HCC15 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, twice a day for 1 month
Result:	Inhibited tumor growth by 30±15%, 72±6% and 82±9% at 10, 30 and 60 mg/kg, respectively.

Animal Model:	Balb/C nude mice, OVCAR3 tumor model
Dosage:	10, 30 and 60 mg/kg
Administration:	PO, once a day for 1 month
Result:	Inhibited tumor growth by 24±26%, 72±17% and 82±10% at 10, 30 and 60 mg/kg, respectively.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (45.81 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8325 mL	9.1624 mL	18.3248 mL
5 mM	0.3665 mL	1.8325 mL	3.6649 mL
10 mM	0.1832 mL	0.9162 mL	1.8325 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.58 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.58 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。